Lp(a)-related relative risk of future coronary heart disease (CHD) events is similar for individuals at very low absolute risk (0/1 cardiovascular risk factors [CVRF]) and for those at elevated absolute risk with ≥2 CVRFs.
AstraZeneca has provided a sponsorship grant towards this independent programme.